Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
Start Today Start Today
// //
Register
AdChoices

Biosyent Inc TSX Venture: RX-X

Today's Change
Volume
Real-Time Last Update TSX Venture Last Sale
Alerts Watchlist Portfolio

Today's Trading

Day Low 7.600
Day High 7.900
Open:7.600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Latest
inside the market
Thursday’s analyst upgrades and downgrades: Rating changes for RBC, National Bank
Subscriber content
inside the market
Thursday’s analyst upgrades and downgrades
Subscriber content
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
inside the market
Monday’s analyst upgrades and downgrades
Subscriber content
inside the market
Monday’s small-cap stocks to watch
Subscriber content
me and my money
One active investor’s recipe for beating the market
Description
Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products. Geographically all the activities are functioned through the region of Canada.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Hold
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
- GlobeNewswire - Wed Apr 14, 10:22AM CDT
GlobeNewswire - CMTX
Wed Apr 14, 10:22AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference. The conference will be held virtually on Tuesday, April 20 and Wednesday, April 21, 2021 between 8:30 am and 5:00 pm ET. Mr. Rene Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent's business and corporate activities on April 21 at 11:00 am. Mr. Goehrum will also be available to meet virtually with investors on a one-on-one basis during the conference. These one-on-one meetings can be requested by attendees after registering for the conference: https://www.meetmax.com/sched/event_71993/conference_register.html.
BioSyent Announces Grant of Restricted Share Units
- GlobeNewswire - Fri Mar 19, 4:33PM CDT
GlobeNewswire - CMTX
Fri Mar 19, 4:33PM CDT
BioSyent Inc. ("BioSyent" or the "Company", TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units "RSUs" to certain directors, officers, management, and employees of the Company pursuant to the Company's Restricted Share Unit Plan (the "RSU Plan"). These RSUs will fully vest within three years on the third anniversary of the applicable grant date.
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020
- GlobeNewswire - Wed Mar 17, 7:37AM CDT
GlobeNewswire - CMTX
Wed Mar 17, 7:37AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020. Key highlights include:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 7.050 +12.06% increase
on 03/17/21
Period Open:7.300
Price movement based on the high, low and last over the given period.
7.900 unch no change
on 04/16/21
 +0.600 (+8.22%) increase
since 03/16/21
3-Month 7.050 +12.06% increase
on 03/17/21
Period Open:7.470
Price movement based on the high, low and last over the given period.
7.990 -1.13% decrease
on 02/17/21
 +0.430 (+5.76%) increase
since 01/15/21
52-Week 3.690 +114.09% increase
on 04/22/20
Period Open:4.150
Price movement based on the high, low and last over the given period.
8.490 -6.95% decrease
on 12/17/20
 +3.750 (+90.36%) increase
since 04/16/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies